There was no substantive reason for it trading near its low of Rs.72/- when most underperforming companies have atleast doubled from their lows. This company is a consistent performer with high profit margin. It is in a niche business of medical transcription. The present global situation show that the demand will only go up.The company is also in the process of restructuring which would ensure future growth. I expect it to reach Rs.130/- in the short term and Rs.210/- within 3 months.
| NIFTY 
